Trial Profile

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs A 400-Sichuan Kelun-Biotech Biopharmaceutical (Primary)
Indications Medullary thyroid cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Ellipses Pharma

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
01 May 2024 According to an Ellipses Pharma Media Release, company announced that the U.S. Food and Drug Administration (FDA) has confirmed the company's next generation selective RET inhibitor (SRI), EP0031/A400, is clear to progress into Phase 2 clinical development.
01 May 2024 According to an Ellipses Pharma Media Release, the latest clinical data from the Ellipses Phase 1 study will be presented at ASCO in Chicago on June 3rd 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com